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ABSTRACT
Ubiquitin speciﬁc protease 33 (USP33) is a multifunctional
protein regulating diverse cellular processes. The expres-
sionand roleofUSP33 in lungcancer remainunexplored. In
this study, we show that USP33 is down-regulated in multi-
ple cohorts of lung cancer patients and that low expression
of USP33 is associated with poor prognosis. USP33 medi-
ates Slit-Robo signaling in lung cancer cell migration.
Downregulation of USP33 reduces the protein stability of
Robo1 in lungcancercells, providingapreviouslyunknown
mechanism for USP33 function in mediating Slit activity in
lung cancer cells. Taken together, USP33 is a new player in
lung cancer that regulates Slit-Robo signaling. Our data
suggest that USP33 may be a candidate tumor suppressor
for lung cancer with potential as a prognostic marker.
KEYWORDS USP33, Slit, Robo, lung cancer, Slit-Robo
signaling, tumor suppressor, prognostic marker
INTRODUCTION
Lung cancer is the most frequently diagnosed of all cancers
and responsible for approximately 1.38 million deaths
worldwide every yearwith anoverall 5-year survival rate∼15%
(Ferlay et al., 2010). Although surgery, radiation, chemother-
apy, and targeted treatments have been developed, these
treatments, even in combinations, are far from satisfactory. A
number of tumor suppressor genes have been discovered in
lung cancer, including TP53, p16, LKB1/STK11, NF1,
RASSF1, APC, BRG1, PTEN, and RB (reviewed in Cooper
et al., 2013; Herbst et al., 2008). A variety of vulnerability
genes have been identiﬁed recently (Kim et al., 2013). How-
ever, endogenous mechanisms that suppress lung cancer
invasion and metastasis remain largely unknown.
Several neuronal guidance molecules have been impli-
cated in cancer invasion and metastasis (Ballard and Hinck,
2012). Originally identiﬁed in Drosophila (Rothberg et al.,
1988), Slit genes encode a family of secreted proteins that act
as neuronal guidance molecules (Bashaw et al., 2000; Brose
et al., 1999; Li et al., 1999; Simpson et al., 2000; Wu et al.,
1999). Recent studies suggest the involvement of Slit genes in
invasion and metastasis of different types of cancers (e.g.,
Biankin et al., 2012; Brantley-Sieders et al., 2011; Dallol et al.,
2003; Yuasa-Kawada et al., 2009a; Tie et al., 2010). Slit acts
by binding to a single-pass transmembrane protein Round-
about (Robo). Our previous data have shown that one of the
Robo-interacting proteins that mediate Slit-Robo signaling is
ubiquitin speciﬁc protease 33 (USP33), also known as von
Hippel-Lindau (VHL)-interacting deubiqutinating enzymes 1,
(VDU1) (Yuasa-Kawada et al., 2009a, b). As a member of
ubiquitin-speciﬁc protease family, USP33 was initially
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discovered as a substrate protein binding to VHL E3 ligase (Li
et al., 2002). USP33 is required for Slit signaling in midline
commissural axon guidance (Yuasa-Kawada et al., 2009b). In
addition, USP33 is involved in Slit signaling in inhibiting breast
caner cellmigration (Yuasa-Kawadaet al., 2009a), suggesting
that USP33may play an important role in cancer invasion and
metastasis.However, the role andmechanismofUSP33 inSlit
signaling in lung cancer remain unknown.
In this study, we demonstrate that USP33 is required for
Slit inhibition of lung cancer cell migration. USP33 regulates
the level of Robo receptor in lung cancer cells. This is distinct
from the USP33 activity in neurons and breast cancer cells
(Yuasa-Kawada et al., 2009a, b). In addition, USP33
appears to have a tumor suppressor function in lung cancer
because low expression of USP33 correlates strongly with
poor survival of lung cancer patients.
RESULTS
USP33 expression is down-regulated in lung cancer
To identify new players and evaluate the potential role of
USP33 in lung cancer, we measured levels of USP33
expression in a panel of lung cancer samples with the mat-
ched adjacent non-tumor lung tissue controls. The level of
USP33 mRNA was analyzed by quantitative RT-PCR.
USP33 expression was signiﬁcantly lower in lung cancer
samples, as compared with adjacent non-tumor lung tissues
(P < 0.001) (Fig. 1A). We next examined USP33 protein
expression in lung cancer samples by immunohistochemical
staining using an antibody speciﬁc for USP33 (Fig. 1B; see
Fig. S1 for the speciﬁcity of anti-USP33). The USP33 staining
signals in the normal lung tissues showed a range from 73.33
to 300.00 (with the mean value as 198.18), whereas those in
the lung cancer samples varied from 0.00 to 266.00 (with the
mean value as 142.38). The USP33 expression levels in lung
cancer samples were signiﬁcantly lower than those in paired
adjacent non-tumor lung tissues (P < 0.01; Fig. 1B and 1C).
To investigate what fraction of lung cancer patients may
have USP33 expression changes, we analyzed a larger
dataset obtained from cBioPortal for Cancer Genomics
(http://cbioportal.org) (Gao et al., 2013). A total of 554 cases
were examined in this cohort. USP33 mRNA down-regula-
tion was detected in 9 lung cancer cases with homozygous
deletion in 2 additional cases and somatic mutations in
another 9 cases (Fig. 2A and 2B). Notably, four USP33
mutations reside inside the catalytic domain of USP33
(Fig. 2B). Thus, approximately 4% of these lung cancer
cases showed homozygous deletion, somatic mutations or
decreased mRNA expression. In addition, somatic USP33
missense mutations were detected in of other cohorts of lung
adenocarcinoma (2.7%–6.2%) and lung squamous cell car-
cinoma (3.4%) samples (Fig. S2). USP33 expression proﬁles
were further examined in datasets from Oncomine database
(http://www.oncomine.org/) (Rhodes et al., 2004), which
contained mRNA proﬁling data from 5 independent cohorts
of lung cancer samples. Remarkably, USP33 mRNA levels
were signiﬁcantly lower in lung cancer samples as compared
with the control samples in all 5 datasets (Fig. 2C). Together,
these results show a highly consistent pattern of down-reg-
ulation of USP33 expression in lung cancer samples.
USP33 expression levels correlate with clinical
outcomes
To examine the relationship between USP33 expression and
the clinical outcome, we analyzed association between
USP33 expression and patient survival by examining publi-
cally available microarray proﬁling datasets for lung cancer.
We generated Kaplan-Meier (KM) survival curves from The
Cancer Genome Atlas (TCGA) datasets (Sanborn et al.,
2011; Zhu et al., 2009) and online KM-Plotter database
(Gyorffy et al., 2010; Gyorffy et al., 2013). For each dataset,
lung cancer patients were classiﬁed into two groups based






















































Figure 1. USP33 expression is down-regulated in
human lung cancer samples. (A) USP33 mRNA level in
25 pairs of lung cancer and adjacent non-cancer lung
control tissues. Values shown (Y axis represents relative
expression units) are normalized to GAPDH. ***P < 0.001.
(B) Immunohistochemical staining of USP33 in lung cancer
and control tissues. a and c, strong positive immunoreac-
tion for USP33 is detected in the cytoplasm. b, USP33-
positive case of lung adenocarcinoma (LuAD). d, USP33-
positive case of lung squamous cell carcinoma (LuSC).
Bar: 50 μm. (C) Quantiﬁcation of USP33 protein expression
in lung cancer (n = 25) and the adjacent control non-cancer
lung tissues (Ctrl) (n = 25). The USP33-immunohistochem-
istry scores are calculated as follows: USP33 immunohis-
tochemistry score = (% of positive tumour cells) × the
staining intensity. USP33 protein expression in lung cancer
samples is signiﬁcantly lower than in the control lung
tissues (**, P < 0.01).
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analysis was used to evaluate survival differences between
the group with high USP33 expression and that with low
USP33 expression. In all four lung cancer datasets in which
survival data are available, higher USP33 expression cor-
relates with longer overall survival of patients (Fig. 3A–D).
We further interrogated the association of USP33
expression with patient survival in other types of cancers.
Similarly, lower expression of USP33 correlated with poorer
survival in a range of other types of cancers, including breast
cancer (BRCA, Fig. 3E and 3F), melanoma (SKCM, Fig. 3G)
and acute myeloid leukemia (AML, Fig. 3H). These data
suggest that USP33 may act as a tumor suppressor gene in
a variety of human cancers.
USP33 is required for Slit signaling in inhibiting lung
cancer cell migration
Previous studies report that Slit expression is reduced in
different types of cancer, including lung cancer and breast
cancer (Dallol et al., 2002) and that Slit plays a role in sup-
pressing lung cancer progression (Tseng et al., 2010). Our
previous work indicates that USP33 is required for Slit sig-
naling in breast cancer (Yuasa-Kawada et al., 2009a). To
understand the mechanism of USP33 function in lung cancer
cells, we investigated the role of USP33 in mediating Slit
suppression of cancer cell migration.
We ﬁrst tested the involvement of USP33 in Slit inhibition
of lung cancer cell migration in a wound healing assay.
H1299 lung cancer cells were treated with either mock
control or Slit containing media following wound formation on
a monolayer culture of H1299 cells. Slit treatment led to a
signiﬁcant reduction in cell migration of H1299 lung cancer
cells. Upon down-regulation of USP33 by a speciﬁc siRNA
against USP33 (siUSP33), the effect of Slit in suppressing
lung cancer cell migration was abolished (Fig. 4A–C), indi-
cating that USP33 is required for Slit signaling in lung cancer
cells. Neither Slit treatment nor USP33 downregulation
affected cell proliferation or cell cycle in these experiments
(Fig. S3 and S4).
To test if the deubiquitinating activity of USP33 plays a
role in mediating Slit activity in lung cancer cells, we used a
construct of USP33 mutant that contained a point mutation,
C163A, in the catalytic domain of USP33 and was capable of
acting in a dominant negative fashion (Yuasa-Kawada et al.,
2009b). Following transfection of H1299 cells with either wild
type (Wt) USP33 or the C163A-mutant USP33 (Mt), H1299
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Figure 2. USP33 expression is reduced in human lung cancer samples obtained from public databases. (A and B) Genetic
alterations and mRNA expression changes of the USP33 in the TCGA dataset of lung cancer samples. USP33 genes are
represented as rows, and individual cases or patients are represented as columns. Genetic alterations are color-coded with red
indicating ampliﬁcation; light blue, homozygous deletion; green box, somatic mutation; pink frame, mRNA upregulation; and blue
frame, mRNA downregulation. These oncoprints are based on data obtained from the Stand Up to Cancer cBio portal (http://cbio.
mskcc.org/su2c-portal/). Higher magniﬁcation images are shown in the insets (B). (C) Five lung cancer gene expression studies are
analyzed using Oncomine (http://www.oncomine.org). USP33 is signiﬁcantly down-regulated at the mRNA level in lung cancer
samples as compared to the control lung tissues in all 5 datasets (Stearman et al., Su et al., Bhattacharjee et al., Landi et al., and Hou
et al.). Box and whisker plots: dots represent maximum and minimum values, whiskers show 90th and 10th percentiles, boxes show
75th and 25th percentiles, and the line indicates the median value. P-values were computed by Oncomine software using Student’s t-
test. Ctrl: control lung tissue samples; LuAD: lung adenocarcinoma; LuSC: lung squamous cell carcinoma.
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cells were treated with control- or Slit-containing medium
(Fig. 4D–F). Expression of the C163A-mutant USP33 abol-
ished Slit suppression of H1299 cell migration, supporting
that deubiquitinating activity of USP33 is important in medi-
ating Slit activity in inhibiting lung cancer cell migration.
USP33 regulates the stability of Robo1
In breast cancer cells, USP33 acts to redistribute Robo1 from
the intracellular compartment to cell surface without affecting
the total level of Robo1 protein (Yuasa-Kawada et al., 2009a).
We asked if USP33 in lung cancer cells acted in a similar
manner as in breast cancer cells. In lung cancer cells, USP33
interacted with Robo1, similar to the observation in the breast
cancer cells, as detected by co-immunoprecipitation experi-
ments (Fig. 5A). Knocking-down USP33 in H1299 cells
increased the level of ubiquitinylated Robo1 in the presence of
MG132, an inhibitor of the ubiquitin proteasome system
(Fig. 5B). Overexpression of wild-type USP33, but not catalyt-
ically inactive C163A mutant of USP33, decreased the ubiqui-
tination of Robo1 (Fig. 5C). Unexpectedly, down-regulation of
USP33 by speciﬁc siRNAs in H1299 cells led to a decrease in
the Robo1 protein level, in contrast to the ﬁndings in breast
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Figure 3. Low USP33 expression correlates with poor patient survival in multiple cancer datasets. Kaplan-Meier curves
showing the overall survival analysis in patients with high and low expression of USP33 from eight public tumor datasets: (A) TCGA
lung data set (AgilentG4502A_07_3 array, n = 91 for USP33 low, n = 91 for USP33 high; P = 0.0436 with log-rank analysis); (B) TCGA
lung data set (IlluminaHiSeq_RNASeqV2 array, n = 106 for USP33 low, n = 106 for USP33 high; P = 0.0267 with log-rank analysis);
(C) Lung cancer dataset (GSE3141) was analyzed by KM plotter. The data were dichotomized at the lower quantile value into high
and low expressing groups (n = 28 for USP33 low, n = 83 for USP33 high; P = 0.031 with log-rank analysis); (D) Lung cancer dataset
(GSE31210) was analyzed by KM plotter. The data were dichotomized at the median value into high and low expressing groups
(n = 113 for USP33 low, n = 113 for USP33 high; P = 0.034 with log-rank analysis). (E) TCGA breast carcinoma data set (n = 61 for
USP33 low, n = 61 for USP33 high; P = 0.0188 with log-rank analysis); (F) Breast cancer data were analyzed by KM plotter. The data
were dichotomized at the median value into high and low expressing groups (n = 562 for USP33 low, n = 553 for USP33 high;
P = 0.0021 with log-rank analysis); (G) TCGA skin cutaneous melanoma data set (n = 145 for USP33 low, n = 150 for USP33 high;
P = 0.0453 with log-rank analysis); (H) TCGA acute myeloid leukemia data set (n = 77 for USP33 low, n = 82 for USP33 high;
P = 0.0282 with log-rank analysis).
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mutant USP33, in H1299 cells increased the levels of Robo1
(Fig. 5E). To examine how USP33 regulates Robo1 protein
stability, H1299 cells were transfected with control siRNA (Ctrl)
or siUSP33, and treated with cycloheximide (CHX, an inhibitor
of protein synthesis) for different periods of time before the
preparation of cell lysates. The Robo1 protein was detected by
Western blotting analyses of cell lysates. At 6 h after CHX
treatment, the Robo1 level decreased; and by 12 h following
CHX treatment, Robo1 protein was almost completely degra-
ded in H1299 cells transfected with siUSP33 compared with
Ctrl siRNA, indicating that knocking-down USP33 shortens the
half-life ofRobo1 (Fig. 5F). Thedecrease ofRobo1protein level
induced by siUSP33 was blocked by treatment with protea-
some inhibitor MG132 (Fig. 5G), suggesting that Robo1 was
degraded mainly through the ubiquitin-proteasome pathway in
H1299. These results indicate that in lung cancer cells, USP33
stabilizes Robo1 protein, preventing it from ubiquitin-protea-
some mediated degradation (Fig. 6).
DISCUSSION
Our results provide evidence that USP33 is a new player in
lung cancer that regulates Slit-Robo signaling. We
demonstrate that expression of USP33 is down-regulated in
lung cancer and associated with clinical outcomes. USP33
mediates the Slit activity in inhibiting lung cancer cell
migration in a manner that is dependent on its catalytic
domain. Furthermore, USP33 stabilizes Robo1 protein by
inhibiting proteasome-dependent degradation. These results
have revealed a previously unknown role of USP33 in
mediating Slit-Robo signaling in lung cancer cells.
USP33 has been implicated in a number of cellular pro-
cesses (Berthouze et al., 2009; Buus et al., 2009; Curcio-
Morelli et al., 2003; Li et al., 2013; Shenoy et al., 2009). Our
study provides, for the ﬁrst time, evidence that USP33 is a
lung cancer associated gene and that its expression is
reduced in lung cancer tissue samples. This down-regulated
expression of USP33 was observed in multiple microarray
datasets of lung cancer and conﬁrmed by qRT-PCR and
immunohistochemical analysis. The higher expression of
USP33 is associated with better prognosis of the lung cancer
patients. The human USP33 gene is located at the chro-
mosome 1p31.1, the region that shows approximately 50%
allelic loss in the NSCLC. In this region, a few tumor sup-
pressor genes have been identiﬁed (Girard et al., 2000). For
example, DnaJ-like heat shock protein (HLJ1) as a tumor









































































Figure 4. USP33 regulates Slit activity in suppressing lung cancer cell migration dependent on its catalytic domain.
(A) Imaging of wound healing of H1299 cells transfected with Ctrl siRNA or siUSP33 and (D) wild-type or mutant (C163A) USP33 was
performed in the presence of mock-control (Ctrl) or Slit. Wound scratches were made so that the cells at the wound edge were
migrating toward the right side in each panel. Images taken at two time points after the wound scratching are shown. The white dotted
lines mark the wound edge at 0 h (Scale bar: 100 μm). (B and E) Quantiﬁcation of the distance of cell migration in the direction toward
the center of the wound. Data are presented as the mean ± SEM. **, P < 0.01 by Mann-Whitney test. (C) Western blot analysis
showing that siUSP33, but not Ctrl siRNA, suppressed expression of endogenous USP33, in H1299 cells. Beta-actin was used as an
internal control. (F) The expression of wild-type and mutant (C163A) USP33 in H1299 cells were conﬁrmed by Western blot. Beta-
actin was used as an internal control.
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inhibit lung cancer cell proliferation, anchorage-independent
growth, tumorigenesis, cell motility, and invasion (Tsai et al.,
2006). The protein kinase cAMP-dependent catalytic beta
(PRKACB) is downregulated in NSCLC tissues, and upreg-
ulation of PRKACB prevents the progression of NSCLC
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Figure 5. USP33 interacts with Robo1 and affects the Robo1 stability in lung cancer cells. (A) Interaction of the endogenous
Robo1 and USP33 proteins in H1299 cells. Coimmunoprecipitation was carried out using either control IgG or anti-Robo1 antibodies
in the presence of mock-control (Ctrl) or Slit. Immunoprecipitated proteins were analyzed by Western blotting with anti-USP33.
(B) Deubiquitination assay was performed in H1299 cells transfected with Robo-HA, Flag-ubiquitin, Ctrl siRNA or siUSP33. Co-
immunoprecipitation was carried out with anti-HA antibodies after MG132 (20 μmol/L) treatment for 6 h. Immunoprecipitated proteins
were examined by Western blotting using corresponding antibodies as indicated. (C) Robo1 deubiquitination was examined in H1299
cells following transfection with Robo-HA, control, wild type or mutant USP33 plasmids. Coimmunoprecipitation was done with anti-
HA antibodies after MG132 (20 μmol/L) treatment for 6 h. Immunoprecipitated proteins were used in Western blotting using
corresponding antibodies as indicated. (D and E) Western blot analysis showing that the levels of the endogenous USP33 and Robo1
proteins in H1299 cells following transfection with siRNAs targeting USP33 #1, USP33#2, and Ctrl siRNA (D) or control, wild type or
mutant USP33 plasmid (E). Beta-actin was used as the internal control. (F) H1299 cells were transfected with siUSP33 and Ctrl
siRNA and treated with CHX (50 μg/mL) for variable lengths of time. The turnover of endogenous Robo1 was determined by Western
blot. Beta-actin was used as the internal control. (G) H1299 cells transfected with siUSP33 and Ctrl siRNA were left untreated or
treated with MG132 (20 μmol/L) for 6 h, then proteins were extracted and subjected to Western blotting analyses. Beta-actin was
used as the internal control.
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that USP33 is a critical player in lung cancer and can be a
potential prognostic biomarker for lung cancer progression.
Recently, altered expression of different genes in the USP
family has been associated with different types of cancers
including lung cancer. For example, USP44 was downreg-
ulated in human lung adenocarcinoma (Zhang et al., 2012).
Patients with lower levels of the USP44 enzyme showed a
signiﬁcantly reduced overall survival (Zhang et al., 2012).
The intragenic homozygous rearrangements and deletions
of the nuclear deubiquitinase (BAP1) have been found in
lung carcinoma cell lines (Ventii et al., 2008). USP1/UAF1
may act as an oncogene, because the inhibitors of USP1/
UAF1 act synergistically with cisplatin in inhibiting cisplatin-
resistant cell proliferation in NSCLC (Chen et al., 2011). Data
presented in this study support that USP33 may be a new
tumor suppressor gene in lung cancer.
In human lung cancer, low expression of Slit2 is associ-
ated with late-stage disease and poor patient survival (Tseng
et al., 2010). Robo1-deﬁcient mice exhibit bronchial epithelial
hyperplasia and focal dysplasia, pathological features asso-
ciated with early-stage lung cancer (Xian et al., 2001). In our
study, Slit2 signiﬁcantly inhibits lung cancer cell migration,
supporting that Slit-Robo signaling suppresses lung cancer.
Our previous study has demonstrated that Slit inhibits
breast cancer cell migration in a mechanism dependent on
USP33 (Yuasa-Kawada et al., 2009a). Our current work
shows that in lung cancer cells, USP33 also interacts with
Robo1 and is required for Slit signaling in inhibiting lung
cancer cell migration. Ubiquitin-mediated modiﬁcation plays
a critical role in regulating protein stability (Ciechanover and
Schwartz, 1994). However, in our previous study, USP33
interacts with Robo1 and is required for Slit-induced Robo1
redistribution to the plasma membrane without affecting the
total Robo1 protein level. Data in this study show that USP33
interacts and stabilizes Robo1 protein level in lung cancer
cells by inhibiting degradation via the ubiquitin proteasome
pathway. USP33 mediates Slit signaling in lung cancer cells,
and this requires the enzymatic activity of USP33, because
expression of USP33 mutant (C163A) abolishes the Slit
activity in lung cancer cells. Interestingly, four missense
mutations in the catalytic domain of USP33 have been
identiﬁed in lung cancer samples in the datasets from the
cBioPortal for Cancer Genomics. It will be interesting to test
whether these mutations affect the catalytic activity of
USP33 in future studies. Our previous work on breast cancer
and the current data from lung cancer suggest that USP33
may mediate Slit signaling in different cancer cells through
different mechanisms.
In summary, our results showed that USP33 expression
was signiﬁcantly decreased in lung cancer tissues. Higher
USP33 expression is associated with better prognosis.
USP33 regulates Slit signaling by stabilizing Robo1 and is
required for Slit inhibition of lung cancer cell migration.
These ﬁndings support that USP33 is a previously unknown
player in lung cancer and suggest that USP33 may be a new
prognostic biomarker for lung cancer.
MATERIALS AND METHODS
Ethical statement
De-identiﬁed lung tumor pathological samples were collected after
pathological diagnosis in Tangdu Hospital, Fourth Military Medical
University, China. Specimens were obtained with informed consent
following approved protocols and following institutional and national
guidelines.
Lung cancer tissues and cell lines
For mRNA extraction, samples were frozen in liquid nitrogen
immediately after surgical removal. For immunohistochemistry, lung
cancer samples were ﬁxed in 10% neutral-buffered formalin over-
night and then parafﬁn embedded sectioned, and stained with
haematoxylin and eosin according to the standard protocol.
H1299 cells and HEK239 cells stably expressing Slit or control
were cultured in Dulbecco’s modiﬁed Eagles medium supplemented
with 10% (v/v) fetal bovine serum, 50 mg/mL penicillin/streptomycin,
incubated at 37°C in a humidiﬁed atmosphere of 5% CO2 as
described previously (Wu et al, 1999).
Antibodies, reagents, and plasmids
Antibodies used were as follows: anti-USP33 (ProteinTech Group,
























Figure 6. A diagram illustrating our working model for
USP33 function in Slit signaling in lung cancer cells. In the
normal lung cells, Slit2 binds to Robo1 and activates down-
stream molecules, modulating the actin cytoskeleton and
inhibiting cell migration. Deubiquitinylating enzyme USP33
reduces the ubiquitination and degradation of Robo1, thereby
stabilizing Robo1 protein. However, in lung cancer cells,
reduced USP33 expression leads to increased ubiquitination
and degradation of Robo1, inactivating Slit signaling in inhibiting
lung cancer cell migration.
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(ProteinTech Group, Inc), anti-Flag (Sigma Aldrich, Inc) and anti-HA
(Covance). Reagents used were as follow: Cycloheximide (CHX)
(Sigma Aldrich, Inc), MG132 (Sigma Aldrich, Inc), Lipofectamine
2000 (Invitrogen, Inc), and enhanced chemiluminescence reagent
kit (ECL; Millipore). Human type II USP33 tagged with GFP at the
N-terminus (GFP-USP33), GFP-USP33C163A mutant constructs,
Robo-HA, Flag-Ub plasmids have been previously described
(Yuasa-Kawada et al., 2009b).
Transfection
Transient transfection with plasmid DNAs was carried out by using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. siRNAs against USP33 (#1: 5′-UCUCGACAGUGGCUUA
AUUAA-3′; #2: 5′-GGAUUCAGUUGGUGAAAUUAC-3′) and negative
control siRNA (5′-CGUACGCGGAAUACUUCGATT-3′) were synthe-
sized by GenePharma Co., Ltd, Shanghai, China. After overnight
incubation, the culture medium was replaced with fresh Dulbecco’s
modiﬁed Eagle’s medium containing 10% fetal bovine serum.
Quantitative RT-PCR
Total RNA was extracted from lung cancer tissues using Trizol
(Invitrogen, Inc). The amount and purity of RNA were measured
spectrophotometrically on Ultrospec 5300 pro (Amersham Biosci-
ences). Genomic DNA was removed from RNA samples by diges-
tion with DNaseI, according to the manufacturer’s instructions. First
strand cDNA was synthesized from 5 μg of total RNA using the oligo
(dT) primers and Moloney Murine Leukemia Virus Reverse Trans-
criptase (M-MLV RT) (Invitrogen, Inc) according to the manufac-
turer’s instructions. Real-Time PCR was used to quantify transcript
levels and performed on the ABI StepOne real-time PCR using
Absolute Blue SYBR green PCR mix (Thermo Fisher Scientiﬁc). The
following primers were used: USP33 (5′-TGTGATGCTTAGGCAAG
GAG-3′ and 5′-GGCCCTCCACCATAAATAGA-3′); Robo1 (5′-GCAT
CGCTGGAAGTAGCCATACT-3′ and 5′-CTAGAAATGGTGGGCT
CAGGAT-3′); GAPDH (5′-GGAGCGAGATCCCTCCAAAAT-3′ and
5′-GGCTGTTGTCATACTTCTCATGG-3′). We used a 2-step ampli-
ﬁcation (40 cycles of 95°C, 15 s; 60°C, 30 s; 72°C, 30 s; followed by
melting temperature determination stage) and fold enrichment was
calculated by the 2−ΔΔCT method.
Immunoprecipitation and Western blotting analyses
Immunoprecipitation and Western blotting analyses were carried out
as previously published (Yuasa-Kawada et al., 2009a). Brieﬂy, 48 h
(for plasmids), or 72 h (for siRNA) after transfection, H1299 cell
lysates were prepared with lysis buffer (0.5% NP-40, 50 mmol/L Tris
[pH 7.5], 150 mmol/L NaCl, 1 mmol/L EDTA, 50 mmol/L NaF,
1 mmol/L Na3VO4, 1 mmol/L DTT, 1 mmol/L PMSF, cocktail).
Cleared cell lysates were used for immunoprecipitation, and immu-
noprecipitated proteins were detected by Western blotting using
corresponding antibodies as indicated.
Immunohistochemistry
Immunohistochemistry was performed on 5 micron-thick, formalin
ﬁxed, parafﬁn-embedded tumor sections, which were initially
deparafﬁnized, rehydrated and heated in citric acid (pH 6.0) for
20 min in a microwave oven. After antigen retrieval, endogenous
peroxidase activity was blocked by 3% hydrogen peroxide for
10 min, followed by 30 min blocking incubation in goat serum (His-
tostain™-Plus Kits; ZSGB-BIO). The slides were then incubated
overnight at 4°C with primary antibody against USP33. Next, the
slides were incubated with biotinylated antibody (Histostain™-Plus
Kits; ZSGB-BIO) for 30 min at room temperature. Finally, slides were
visualized by 3,3-diaminobenzidine (DAB) staining. Stained slides
were digitalized with Scanscope XT (Aperio Technologies, Vista,
CA). To quantitate the state of USP33 protein expression, the mean
percentage of positive tumour cells was determined in at least ﬁve
random ﬁelds at 200× magniﬁcation in each section. The intensity of
the USP33-immunoreaction was scored as follows: 0, negative; 1+,
weak; 2+, moderate; and 3+, intense. The percentage of positive
tumour cells and the staining intensity then were multiplied to pro-
duce the USP33-immunohistochemical staining score.
Recombinant Slit2 production and wound healing assay
The HEK293 cells that produce full-length Slit2 proteins tagged with
c-myc have been described (Wu et al., 2001). The cells were cul-
tured in DMEM with 5% FBS. Slit2 was partially puriﬁed from the
supernatants as described previously (Wu et al., 2001). The
supernatant from parental HEK cells was used as mock control.
For wound healing assay, H1299 cells were seeded on photo-
etched grid coverslips coated with collagen in 35 mm culture. Once
the cells reached conﬂuence, a wound area was carefully created by
scraping the cell monolayer with a sterile 10 μl pipette tip. The cells
were rinsed with PBS to remove detached cells and then allowed to
grow in the presence of control- or Slit- containing media. Ten ima-
ges were taken under an inverted microscope at 0 and 12–16 h
following the wound formation. Cell migration was quantiﬁed by
measuring the forward migration distance of cells from the original
position of the wound formation.
Analyses of USP33 gene expression in human cancer samples
Genetic alterations and mRNA expression changes of the USP33
were presented analyzed in the data from cBioPortal for Cancer
Genomics (Gao et al., 2013). Correlations between lung cancer and
USP33 gene expression were determined through analysis of
Stearman, Su, Bhattacharjee, Landi and Hou lung cancer datasets,
respectively, which are available through Oncomine (http://www.
oncomine.org/) (Rhodes et al., 2004). The correlations between lung
cancer patients’ survival and USP33 gene expression were ana-
lyzed using TCGA data from Cancer browser database (https://
genome-cancer.ucsc.edu/) (Zhu et al., 2009) and the online KM-
Plotter database (Gyorffy et al., 2010; Gyorffy et al., 2013).
Statistical analysis
All grouped data are presented as mean ± SEM. To determine sta-
tistical signiﬁcance, results were compared by means of paired t-test
(for two samples) or by analysis of variance (ANOVA) (for more than
two samples). For survival analyses, Kaplan-Meier curves were
generated using Prism software and log-rank analysis performed. All
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experiments presented were repeated at least three times. P < 0.05
at the 95% conﬁdence level was considered signiﬁcant.
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